National Research (NASDAQ:NRC) Posts Earnings Results

National Research (NASDAQ:NRC) posted its quarterly earnings data on Tuesday. The company reported $0.16 EPS for the quarter, FiscalAI reports. The firm had revenue of $35.19 million during the quarter. National Research had a return on equity of 98.26% and a net margin of 11.76%.

Here are the key takeaways from National Research’s conference call:

• TRCV reached $144.1 million (up 8% YoY) and marked five consecutive quarters of sequential TRCV growth, with 99% of revenue recurring, and management expects revenue growth to follow as TRCV converts in 2026.
• Q4 revenue was $35.2 million (down 5% YoY) and full-year revenue fell 4% to $137.4 million, driven by unusually heavy TRCV attrition in H2 2024 that created difficult year-over-year comparisons.
• Profitability remained strong with full-year adjusted EBITDA of $40.2 million (~29% margin) and Q4 adjusted EBITDA of $8.7 million, supporting continued investment while maintaining disciplined cost management.
• Go-to-market and product investments are gaining traction—full-year new sales rose 86% YoY, gross dollar retention hit a >7‑year high, and enablement products like Rounding (TRCV nearly doubled) plus AI enhancements are cited as key growth catalysts and cross-sell opportunities.
• Management reiterated a shareholder-friendly capital allocation approach, paying a quarterly dividend of 12 cents, maintaining opportunistic share repurchases, and preserving flexibility for strategic, accretive M&A.

National Research Stock Down 19.5%

Shares of NASDAQ NRC opened at $17.62 on Wednesday. The stock has a market capitalization of $399.27 million, a PE ratio of 25.17 and a beta of 0.49. The company has a quick ratio of 0.53, a current ratio of 0.53 and a debt-to-equity ratio of 5.31. The firm has a fifty day moving average of $18.99 and a 200-day moving average of $15.91. National Research has a 52-week low of $9.76 and a 52-week high of $22.79.

National Research Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 10th. Shareholders of record on Friday, March 27th will be issued a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 3.6%. The ex-dividend date is Friday, March 27th. National Research’s dividend payout ratio (DPR) is 91.43%.

Analyst Ratings Changes

Separately, Weiss Ratings lowered shares of National Research from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, January 28th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

Hedge Funds Weigh In On National Research

Large investors have recently modified their holdings of the company. Willis Investment Counsel grew its holdings in shares of National Research by 175.2% during the 2nd quarter. Willis Investment Counsel now owns 180,999 shares of the company’s stock worth $3,041,000 after purchasing an additional 115,221 shares during the period. Creative Planning increased its position in shares of National Research by 319.2% in the second quarter. Creative Planning now owns 147,413 shares of the company’s stock worth $2,477,000 after acquiring an additional 112,251 shares in the last quarter. AQR Capital Management LLC raised its stake in shares of National Research by 86.2% in the 2nd quarter. AQR Capital Management LLC now owns 201,396 shares of the company’s stock valued at $3,383,000 after acquiring an additional 93,262 shares during the period. Jane Street Group LLC lifted its holdings in shares of National Research by 394.2% during the 1st quarter. Jane Street Group LLC now owns 52,411 shares of the company’s stock valued at $671,000 after acquiring an additional 41,806 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its position in National Research by 180.8% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 49,076 shares of the company’s stock worth $627,000 after purchasing an additional 31,599 shares during the period. 47.26% of the stock is currently owned by hedge funds and other institutional investors.

National Research Company Profile

National Research Corp (NASDAQ: NRC), also known as NRC Health, is a healthcare analytics and performance improvement company specializing in patient and employee experience measurement. The company’s cloud-based platform enables healthcare providers to collect real-time feedback through patient satisfaction surveys, post-discharge outreach, and employee engagement tools. NRC Health integrates clinical, operational and financial data to deliver actionable insights that support quality improvement initiatives and value-based care programs.

Since its founding in the early 1990s and headquartered in Lincoln, Nebraska, National Research has expanded beyond its regional roots to serve more than 1,600 hospitals and 12,000 care sites across the United States and Canada.